Third International Congress Drug Therapy in HIV Infection 3-7 November 1996 Glasgow, UK

THE EFFECT ON CEREBROSPINAL FLUID HIV RNA LEVELS AFTER INITIATION OF ZIDOVUDINE OR DIDANOSINE

M. Gisslén, G. Norkrans, B. Svennerholm, L. Hagberg
Department of Infectious Diseases, Östra University Hospital, S-41685 Göteborg, Sweden (e-mail: magnus.gisslen@medfak.gu.se)

Int Cong Drug Therapy HIV 1996 Nov 3-7;3:Abstract No. OP2.3
AIDS 1996, Vol. 10 (Suppl. 2);S10

To evaluate the effect of zidovudine and didanosine on cerebrospinal fluid (CSF) HIV RNA levels, CSF and serum samples were collected, before and 3-13 months after initiation of treatment. Twentyone monotherapy treatment periods, 13 after initiation of zidovudine and 8 after initiation of didanosine were studied in 16 HIV-1 infected individuals. HIV RNA levels (Roche HIV Monitor), neopterin, and ß2-microglobulin concentrations were analysed in CSF and serum.

CSF WV RNA levels decreased with in mean 1.05 log (-91%, p<0.01) during zidovudine treatment. No reduction was seen during didanosine treatment (+0.13 log, ns). CSF neopterin and ß2-microglobulin decreased significantly after initiation of zidovudine (-57%, and -33% respectively, p<0.01), while an increase in CSF neopterin and ß2-microglobulin followed didanosine treatment (ns). Changes in CSF HIV RNA levels correlated with changes in CSF neopterin and ß2-microglobulin (r₅=0.81 and 0.83, respectively, p<0.0001). The decrease in HIV RNA was significantly larger in CSF than in serum following zidovudine treatment (p<0.01) and was maintained in all four patients analysed with more than 12 months of treatment.

We conclude that zidovudine is a potent reducer of CNS viral load which is important for long teen neuroprotection.

Presenting author: M. Gisslén

1996-11-03
OP2.3

Originally published in AIDS Volume 10, Supplement 2 and hosted with permission of the publisher Lippincott Williams & Wilkins, 250 Waterloo Road, London, SE1 8RD, UK. Tel: +44 (0)20 7981 0700 Fax: +44 (0) 7981 0701

Copyright © 1996 - Lippincott Williams & Wilkins. All rights reserved. All abstracts from the 3rd International Congress Drug Therapy in HIV Infection, appearing on the AEGiS web site, are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Lippincott Williams & Wilkins. You may not alter or remove any trademark, copyright or other notice. However, provided that you maintain all copyright and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only.

http://www.aidsonline.com http://www.ovid.com